OasisLMS

This webinar, presented in collaboration with the Japan Lung Cancer Society (JLCS), the Taiwan Association for the Study of Lung Cancer (TASLC), and the International Association for the study of Lung Cancer (IASLC), examines the evolving treatment landscape for non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations and a comparative discussion of thoracic oncology practice in Japan and Taiwan.

This webinar reflects our shared commitment to advancing thoracic oncology through international collaboration, knowledge exchange, and regional perspectives.

This activity is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer including medical oncologists, thoracic surgeons, radiation oncologists, radiologists, pathologists, advanced practice nurses and physician associates.

Upon completion of this activity, the participants should be able to:

• Describe the biology and clinical significance of EGFR exon 20 insertion mutations in non-small cell lung cancer (NSCLC).
• Summarize current and emerging treatment strategies for NSCLC with EGFR exon 20 insertion mutations, including amivantamab-based regimens and novel targeted therapies.
• Discuss approaches to toxicity management and supportive care in the context of evolving treatment options for EGFR exon 20 insertions mutations.
• Compare the thoracic oncology landscapes in Japan and Taiwan, including differences in healthcare systems, reimbursement models, and access to care.
• Evaluate access to molecular testing and targeted therapies across regions and how these factors influence treatment decision-making.

• Kuan-Yu Chen, MD, PhD, National Taiwan University Hospital and College of Medicine, Taipei, Taiwan
• James Chih-Hsin Yang, MD, PhD, National Taiwan University, Taipei, Taiwan
• Bin-Chi Liao, MD, National Taiwan University Cancer Center, Taipei, Taiwan
• Hidehito Horinouchi, MD, PhD, National Cancer Center Hospital, Tokyo, Japan
• Makoto Nishio, MD, PhD, The Cancer Institute Hospital of JFCR, Tokyo, Japan

The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

If you need any assistance with this activity, please email: education@iaslc.org.